Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists fr
Post# of 420
(Total Views: 260)
Posted On: 07/12/2021 3:50:07 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes
- Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects
- The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular entities
- Lexaria announced voluntary delisting from the Canadian Securities Exchange this month in order to focus its resources more effectively on its Nasdaq listing
- The company’s leadership recently interacted with investors in the Life Sciences Investor Forum virtual conference series and the company’s annual meeting
The apex of the summer season is a time for movie studios to roll out their most-anticipated productions, TV fans and gamers to pore over lists of new releases and young sun-seekers to enjoy fun business promotions ranging from amusement park activities to themed food events before the looming return to school.
As the COVID-19 pandemic continues to occupy headlines worldwide, pharmaceutical companies are working toward announcements of a more sober nature, introducing advances toward potential solutions for the global health crisis as well as other medical concerns lacking such a large level of publicity at this moment in history.
Drug bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) recently announced expectations that its R&D program will soon yield reporting on a number of key programs partnering Lexaria’s IP with pandemic-target antivirals, NSAIDs and other products studying hypertension and oral nicotine (https://nnw.fm/suHzK).
To further the company’s efforts to focus its capital and other resources on Lexaria’s applied research and development programs, the global innovator in drug delivery platforms announced earlier this month that it had chosen to delist its common shares from the Canadian Securities Exchange (CSE ticker LXX) effective July 8, at which point the company’s shares will only trade on the Nasdaq Capital Markets.
“Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq, providing more liquidity for shareholders than ever before experienced. The Company expects to realize savings in fees and managerial time and effort that were required to maintain a dual listing,” the announcement states (https://nnw.fm/irYbA).
The announcement adds that securities listed with Nasdaq are designated as a “qualified investment” to maintain Lexaria shares in Canadian Registered Savings Plans, including RRSP, RESP, RRIF, RDSP and TFSA.
Lexaria’s DehydraTECH IP is designed to convert drugs into a powdered or liquid form that will make them orally ingestible with quick absorption and efficacy comparable to the bioavailability experienced by inhaling smoked drugs, but without the harmful lung effects smoking can produce.
The key R&D programs nearing reporting stage this month are evaluating DehydraTECH’s tolerability and pharmacokinetics (also known as “PK,” or its chemical life cycle from administration to elimination from the body) within animal test subjects; assessing DehydraTECH’s ability to avoid altering the partner drug to such a degree that it would create covalently-bonded new molecular entities (“NMEs”) that would trigger additional regulatory concerns; and, much-anticipated results related to its first human clinical study on utilizing DehydraTECH-processed CBD for purposes of treating hypertension .
Lexaria participated in June’s Life Sciences Investor Forum virtual conference series, which facilitates global investor audience interaction with presenting companies. The company’s presentation is now available for on-demand viewing at the conference’s website for a limited time (https://nnw.fm/96cRw).
Lexaria also recently conducted its annual meeting with investors, and has announced the results of voting on board directors, the company’s auditors, and a pair of proposals related to share issuance and other corporate decisions (https://nnw.fm/mNzjv).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects
- The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular entities
- Lexaria announced voluntary delisting from the Canadian Securities Exchange this month in order to focus its resources more effectively on its Nasdaq listing
- The company’s leadership recently interacted with investors in the Life Sciences Investor Forum virtual conference series and the company’s annual meeting
The apex of the summer season is a time for movie studios to roll out their most-anticipated productions, TV fans and gamers to pore over lists of new releases and young sun-seekers to enjoy fun business promotions ranging from amusement park activities to themed food events before the looming return to school.
As the COVID-19 pandemic continues to occupy headlines worldwide, pharmaceutical companies are working toward announcements of a more sober nature, introducing advances toward potential solutions for the global health crisis as well as other medical concerns lacking such a large level of publicity at this moment in history.
Drug bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) recently announced expectations that its R&D program will soon yield reporting on a number of key programs partnering Lexaria’s IP with pandemic-target antivirals, NSAIDs and other products studying hypertension and oral nicotine (https://nnw.fm/suHzK).
To further the company’s efforts to focus its capital and other resources on Lexaria’s applied research and development programs, the global innovator in drug delivery platforms announced earlier this month that it had chosen to delist its common shares from the Canadian Securities Exchange (CSE ticker LXX) effective July 8, at which point the company’s shares will only trade on the Nasdaq Capital Markets.
“Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq, providing more liquidity for shareholders than ever before experienced. The Company expects to realize savings in fees and managerial time and effort that were required to maintain a dual listing,” the announcement states (https://nnw.fm/irYbA).
The announcement adds that securities listed with Nasdaq are designated as a “qualified investment” to maintain Lexaria shares in Canadian Registered Savings Plans, including RRSP, RESP, RRIF, RDSP and TFSA.
Lexaria’s DehydraTECH IP is designed to convert drugs into a powdered or liquid form that will make them orally ingestible with quick absorption and efficacy comparable to the bioavailability experienced by inhaling smoked drugs, but without the harmful lung effects smoking can produce.
The key R&D programs nearing reporting stage this month are evaluating DehydraTECH’s tolerability and pharmacokinetics (also known as “PK,” or its chemical life cycle from administration to elimination from the body) within animal test subjects; assessing DehydraTECH’s ability to avoid altering the partner drug to such a degree that it would create covalently-bonded new molecular entities (“NMEs”) that would trigger additional regulatory concerns; and, much-anticipated results related to its first human clinical study on utilizing DehydraTECH-processed CBD for purposes of treating hypertension .
Lexaria participated in June’s Life Sciences Investor Forum virtual conference series, which facilitates global investor audience interaction with presenting companies. The company’s presentation is now available for on-demand viewing at the conference’s website for a limited time (https://nnw.fm/96cRw).
Lexaria also recently conducted its annual meeting with investors, and has announced the results of voting on board directors, the company’s auditors, and a pair of proposals related to share issuance and other corporate decisions (https://nnw.fm/mNzjv).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼